Summary of findings 2. Performance of gNIPT for detection of T21.
Performance of gNIPT for detection of T21 | |||||||
Test strategy |
Number of studies |
Number of affected pregnancies (Number of unaffected pregnancies)a |
Sensitivity % (95% CI) |
Specificity % (95% CI) |
Median prevalenceb % (range) |
Missed cases (FN)c |
False positives (FP)d |
Unselected pregnant women | |||||||
MPSS | 1 | 8 (1733) | 100 (67.6 to 100) | 100 (99.8 to 100) | 0.46 (0.24 to 5.21) |
0 | 0 |
TMPS | 4 | 88 (20,679) | 99.2 (78.2 to 100) | 100 (> 99.9 to 100) | 4 | 0 | |
Traditional screening teste | 1 | 38 (15,803) | 78.9 (63.7 to 88.9) | 94.6 (94.2 to 94.9) | 97 | 5375 | |
Implications |
|
||||||
Selected high‐risk pregnant women | |||||||
MPSS | 30 | 1048 (15,937) | 99.7 (98.0 to 100) | 99.9 (99.8 to 100) | 4.95 (0.44 to 27.66) |
15 | 95 |
TMPS | 6 | 246 (4380) | 99.2 (96.8 to 99.8) | 100 (99.8 to 100) | 40 | 0 | |
Difference between MPSS and TMPS | 0.53 (‐0.73 to 1.78) | ‐0.03 (‐0.11 to 0.04) | NA | ||||
Implications |
|
MPSS: massively parallel shotgun sequencing, NA; not applicable, TMPS: targeted massively parallel sequencing, T21: trisomy 21.
aUnaffected pregnancies: we included patients with any other aneuploidy than the one under analysis with all euploid cases as "unaffected" pregnancies.
bThe median prevalence and range were calculated by using all prospective or retrospective studies for each category considered.
cMissed cases per 100,000 tested. FN: false negatives.
dFalse positives per 100,000 tested. A false positive result may lead to unnecessary invasive tests depending on choices by the pregnant woman.
eTraditional screening tests are first‐trimester combined test, second‐trimester quadruple test, second‐trimester fully integrated test, second‐trimester sequential test or second‐trimester triple test.